

10. ~~The use of a~~A compound as claimed in any of the preceding claims, or a pharmaceutically-acceptable salt thereof ~~for use in the~~ manufacture of a medicament for the prevention or treatment of cancer in a warm blooded animal such as man.

5 11. ~~A combination suitable for use in the treatment of cancer~~ The use of a combination comprising a compound of Formula (I) as claimed in claim 1 or a pharmaceutically acceptable salt thereof and another anti-tumour agent in the manufacture of a medicament for the treatment of cancer.

10 12. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically-acceptable salt thereof, as claimed in claim 1, and a pharmaceutically-acceptable diluent or carrier.

13. A method for selecting a patient for treatment with a compound of Formula (I), the
15 method comprising providing a sample from a patient containing tumour-derived DNA or tumour cells; determining whether the PIK3CA gene in the patient's tumour cells or tumour-derived DNA are wild type or mutant; and selecting a patient for treatment with a compound of Formula (I) based thereon.

20 14. ~~A method of treating a patient suffering from cancer comprising: providing a tumour cell containing sample from a patient; determining whether the PIK3CA gene in the patient's tumour cells are wild type or mutant; and administering to the patient an~~ The use of an effective amount of a compound of Formula (I) as claimed in claim 1 in the manufacture of a medicament for the treatment of cancer, wherein the medicament is
25 administered to a patient if a sample of the patient has been provided and the PIK3CA gene in the patient's tumour cells has been determined to be wild type or mutant, and if the
~~tumour~~the tumour cells possess a mutant PIK3CA gene.

30 15. ~~A~~ The use of a compound of Formula (I) as claimed in claim 1 in the manufacture of a medicament for the treatment of ~~for treating~~ cancers with tumour cells identified as harbouring a mutant PIK3CA gene.